Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study on Dose Optimization of Fruquintinib in Elderly Metastatic Colorectal Cancer Patients Refractory to Standard Treatment

NCT05025631 is registered in ClinicalTrials.gov with Zhen-Yu Ding as lead sponsor.

NCT NCT05025631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05025631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study on Dose Optimization of Fruquintinib in Elderly Metastatic Colorectal Cancer Patients Refractory to Standard Treatment
Lead sponsor
Zhen-Yu Ding
Phase
Phase 2
Overall status
Completed
Start date
November 6, 2020
Completion date
October 30, 2022
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer